Cost-Effectiveness Analysis of Biomarker-Guided Treatment for Metastatic Gastric Cancer in the Second-Line Setting

Figure 1

Model schematic. The top plot (a) illustrates treatment strategies with all patients receiving the same treatment, and the bottom plot (b) illustrates personalized treatment based on biomarker status. The biomarkers are programmed death ligand-1 (PD-L1) with a combined positive score (CPS) >1%, or high microsatellite instability (MSI-H).

(a)

(b)